Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) (NCT00143975)
Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) 3g/m² day 1 Cytarabine (DepoCyt®; Sigma Tau Pharmaceuticals) 3g/m² bid days 1-3 Mitoxantrone 12mg/m² days 2,3 all-trans-Retinoid Acid (Vesanoid®;Genentech/ Roche, Inc.) 45mg/m² days 4-6 and 15 mg/m² days 7-28.
This trial is sponsored by University of Ulm. 
- Condition: Acute Myeloid Leukemia
- Phase: II
- Enrollment: 95
- Start: June 2004
- Completion: June 2009
- Last verified: August 2010
Last Editorial review: July 21, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.